Anebulo Pharmaceuticals, Inc. (ANEB) Stock

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing innovative treatments for acute cannabinoid intoxication (ACI) and substance addiction. At the forefront of its pipeline is ANEB-001, a promising small molecule cannabinoid receptor antagonist currently undergoing Phase II clinical trials. This candidate aims to meet the critical medical need for a targeted antidote to address ACI, providing potential relief and improved outcomes for affected individuals.

Established in 2020 and headquartered in Lakeway, Texas, Anebulo Pharmaceuticals is dedicated to advancing scientific research and therapeutic solutions in the field of cannabinoid-related disorders. The company's commitment to innovation is underscored by its strategic focus on developing effective treatments that can make a meaningful impact on patient care and public health.

With ANEB-001 progressing through clinical trials, Anebulo Pharmaceuticals aims to leverage its expertise and resources to bring novel therapies to market swiftly. By addressing significant gaps in treatment options for ACI and substance addiction, the company seeks to enhance patient outcomes and establish itself as a leader in cannabinoid pharmacology.